Physician profile
Robert J Holzhauer
NPI 1710955976
$5,875.76
in general payments reported to CMS, 2019-2025
27 companies · $1,068 in 2025
The $1,068 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $254 · 2021: $596 · 2022: $1,085 · 2023: $1,269 · 2024: $759 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.84 |
| Education | $124.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,736.53 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $615.20 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $521.27 | 2019-2025 | |
| Csl Behring | $365.62 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Grifols USA, LLC | $346.70 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $279.46 | 2019-2025 | Dupixent |
| Octapharma USA, INC. | $275.84 | 2019-2023 | Cutaquig |
| Takeda Pharmaceuticals U.S.A., INC. | $269.53 | 2020-2024 | Takhzyro, Cuvitru, Eohilia |
| Novartis Pharmaceuticals Corporation | $241.97 | 2019-2025 | |
| Amgen INC. | $177.61 | 2021-2025 | Tezspire, Actimmune |
| Blueprint Medicines Corporation | $163.09 | 2023-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.32 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Biocryst US Sales Co., LLC | $93.51 | 2022-2025 | Orladeyo |
| Genentech USA, INC. | $92.16 | 2024-2025 | Xolair |
| Pharming Healthcare, INC. | $89.06 | 2022-2025 | Ruconest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $74.31 | 2025 | Dawnzera |
| Ars Pharmaceuticals Operations, INC. | $57.70 | 2025 | Neffy |
| Pfizer INC. | $53.36 | 2021-2023 | |
| Optinose US, INC. | $53.16 | 2019-2023 | |
| Shire North American Group INC | $38.74 | 2019 | |
| Lilly USA, LLC | $29.10 | 2024 | Ebglyss |
| Merck Sharp & Dohme LLC | $28.32 | 2023 | |
| Cycle Pharmaceuticals INC | $27.72 | 2025 | Sajazir |
| Bio Products Laboratory USA, INC. | $24.61 | 2022 | |
| Alk-Abello, INC | $23.86 | 2023 | Odactra, Ragwitek, Grastek |
| Kaleo, INC. | $21.75 | 2021 | |
| Leo Pharma INC. | $19.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Holzhauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.